![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Summit Therapeutics Inc | NASDAQ:SMMT | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.01 | 0.11% | 9.48 | 9.47 | 9.76 | 1,020 | 11:02:21 |
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
Summit Therapeutics to Host R&D Day 7 October 2019
Oxford, UK, and Cambridge, MA, US, 25 September 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announces that it will host a research and development day for investors and media on 7 October 2019 from 8am-12pm EDT in New York City.
The event will feature leading experts: Dr Casey Theriot, of North Carolina State University, on the role of the microbiome in C. difficile infection (‘CDI’) and Dr Kevin Garey, of the University of Houston, on the economic and patient impact of CDI. Summit’s management team will provide insight on the Company’s precision antibiotic ridinilazole as a potential front-line treatment for CDI, which is currently in Phase 3 clinical trials. In addition, management will discuss the Company’s Discuva Platform, aimed at discovering novel class, targeted antibiotics for serious infectious diseases.
A live webcast of the event will be available in the Investors section of the Company's website, www.summitplc.com. A replay of the webcast will be available from the same location soon after the conclusion of the live presentation.
For further details, or to request an invitation, email investors@summitplc.com.
About Summit Therapeutics Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.
Contacts
Summit | ||
Glyn Edwards / Richard Pye (UK office) | Tel: | 44 (0)1235 443 951 |
Michelle Avery (US office) | +1 617 225 4455 | |
Cairn Financial Advisers LLP (Nominated Adviser) | Tel: | +44 (0)20 7213 0880 |
Liam Murray / Tony Rawlinson | ||
N+1 Singer (Joint Broker) | Tel: | +44 (0)20 7496 3000 |
Aubrey Powell / Jen Boorer, Corporate FinanceTom Salvesen, Corporate Broking | ||
Bryan Garnier & Co Limited (Joint Broker) | Tel: | +44 (0)20 7332 2500 |
Phil Walker / Dominic Wilson | ||
MSL Group (US) | Tel: | +1 781 684 6652 |
Erin Anthoine | summit@mslgroup.com | |
Consilium Strategic Communications (UK) | Tel: | +44 (0)20 3709 5700 |
Mary-Jane Elliott / Sue Stuart / Sukaina Virji | summit@consilium-comms.com | |
Lindsey Neville |
-END-
1 Year Summit Therapeutics Chart |
1 Month Summit Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions